Clinical Trial Update: Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of Iodine-131 and Pazopanib in patients with recurrent or metastatic thyroid cancer that cannot be removed surgically.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Cancer
• Papillary Thyroid Cancer

Drugs mentioned

• Iodine-131 (Iodine-131)
• Pazopanib (Pazopanib)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer | Phase 1 | Status: COMPLETED